SmartCells, a privately held insulin developer, has received a buyout offer from Merck & Co. that is potentially worth more than US$500 M if development and regulatory milestones are met. With the acquisition, Merck will gain SmartInsulin™, a preclinical, glucose-responsive insulin technology that is being developed for the treatment of type 1 diabetes.